Skip to main content

Mid-Year Meeting 2023 Main banner

Browse by Speaker

Browse by Speaker

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

G
Galárraga, Omar

Brown University
OP2-2 - Impact of Myocardial Infarction on Statin Adherence among Medicaid Beneficiaries in 14 States from 2001 to 2015
Location: Room A
Omar Galárraga
Gao, Yaqing

Oxford University
OP4-6 - Common comorbidities and COVID-19 mortality: an empirical comparison of primary care alone vs additional hospital data linkage for association analyses
Location: Room A
Yaqing Gao
Gardarsdottir, Helga

Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands
Pandemic Driven (Real-World) Data Shifts
Location: Room A
Helga Gardarsdottir
OP4-2 - Review of studies evaluating the effectiveness of risk minimization measures assessed by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency during 2016-2021
Location: Room A
Helga Gardarsdottir
OP4-3 - Description of the delay in completion of studies that evaluate the effectiveness of additional risk minimization measures
Location: Room A
Helga Gardarsdottir
Geier, Jamie

Novartis Pharma AG
Future Innovation and Outlook for the Field of Pharmacoepidemiology
Location: Room a
Jamie Geier
Gerbier, Eva

Pharmacy department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
OP1-3 - Determinants of vaccination and willingness to vaccinate against COVID-19 among pregnant and postpartum women during the third wave of the pandemic: A European Multinational cross-sectional survey
Location: Room A
Eva Gerbier
Gerhard, Tobias

Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research
Pandemic Driven (Real-World) Data Shifts
Location: Room A
Tobias Gerhard
Principles of Pharmacoepidemiology
Location: Room A
Tobias Gerhard
Gillies, Malcolm

School of Population Health, University of New South Wales
OP1-6 - Prenatal exposure to antipsychotic medication and neurocognitive impairment among children: A Nordic cohort study
Location: Room A
Malcolm Gillies
Gini, Rosa

ARS Toscana, Florence, Italy
OP1-4 - Distinguishing between indications for use of medications in administrative data sources Application to pregabalin and gabapentin A contribution from the ConcePTION project
Location: Room A
Rosa Gini
Gissler, Mika

Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki
OP1-4 - Distinguishing between indications for use of medications in administrative data sources Application to pregabalin and gabapentin A contribution from the ConcePTION project
Location: Room A
Mika Gissler
OP1-6 - Prenatal exposure to antipsychotic medication and neurocognitive impairment among children: A Nordic cohort study
Location: Room A
Mika Gissler
Goedecke, Thomas

European Medicines Agency
OP4-2 - Review of studies evaluating the effectiveness of risk minimization measures assessed by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency during 2016-2021
Location: Room A
Thomas Goedecke
Goodman, Michael

Emory University
OP1-1 - Hormone therapy and risk of venous thromboembolism in transgender women
Location: Room A
Michael Goodman
Grupstra, Renske

Utrecht University
OP4-2 - Review of studies evaluating the effectiveness of risk minimization measures assessed by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency during 2016-2021
Location: Room A
Renske Grupstra
Gudmundsson, Larus

University of Iceland
Real Time Use of Real-World Data for Decision-Making
Location: Room A
Larus Gudmundsson
Real-World Data for Precision Medicine: A Pharmacoepidemiological Perspective
Location: Room A
Larus Gudmundsson